Authorization

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

-A Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population-A In the overall population, elacestrant reduced risk of progression or death by 30% vs. SoC- In the mESR1 population, elacestrant reduced risk of progression or death by 45% vs. SoC-A PFS rate at 12 months with elacestrant was 22.32% versus 9.42% with SoC in the overall population, and 26.76% versus 8.19% in the mESR1 population-A Compared to fulvestrant, elacestrant demonstrated statistically significant PFS and reduced the risk of progression or death by 32% in the overall population and 50% in the mESR1 population
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
24252627282930
31